XML 30 R40.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Subsequent Events (Details) In Millions, unless otherwise specified | Oct. 21, 2014 USD ($) | Oct. 21, 2014 EUR (€)
--- | --- | ---
Subsequent Event [Line Items] |  |
Ipsen Upfront Payment | $ 23 |
Ipsen Regulatory And Commercial Launch Milestones | 30 |
Ipsen Sales Milestones |  | € 72

X
- Definition On October 21, 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development of Lexicon's drug candidate LX1032 (telotristat etiprate) outside the United States, Canada and Japan. This represents the potential regulatory and commercial launch milestone payments under the agreement. + References No definition available. + Details
Name: | lxrx_IpsenRegulatoryAndCommercialLaunchMilestones
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition On October 21, 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development of Lexicon's drug candidate LX1032 (telotristat etiprate) outside the United States, Canada and Japan. This represents the potential sales milestone payments under the agreement. + References No definition available. + Details
Name: | lxrx_IpsenSalesMilestones
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition On October 21, 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development of Lexicon's drug candidate LX1032 (telotristat etiprate) outside the United States, Canada and Japan. This represents the upfront payment under the agreement. + References No definition available. + Details
Name: | lxrx_IpsenUpfrontPayment
Namespace Prefix: | lxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_SubsequentEventLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration